KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$6.72 USD
+0.27 (4.19%)
Updated May 31, 2024 04:00 PM ET
After-Market: $6.73 +0.01 (0.15%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
Brokerage Reports
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 221 - 240 ( 365 total )
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Fallout Has Little Impact on Overall Valuation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
STRIDE 3 Delivers; EYSUVIS Resubmission in 2Q20; Raising PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Plenty of Cash to Cover Key Catalysts; Next: Resubmission of DED NDA in Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L